EA
SRPT icon

Emerald Acquisition’s Sarepta Therapeutics SRPT Stock Holding History

Emerald Acquisition’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$1.43M Sell
23,351
-2,653
-10% -$80.2K ﹤0.01% 1932
2016
Q2 		$496K Buy
+26,004
New +$482K ﹤0.01% 2472

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
TCP
Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Emerald Acquisition's SRPT Position: Q3 2016 in Review

Emerald Acquisition reduced its Sarepta Therapeutics (SRPT) stake by 10% in Q3 2016, selling an estimated $80.2K and leaving 23,351 shares worth $1.43M. The position accounts for ﹤0.01% of the portfolio, ranked #1932.

Emerald Acquisition first reported a position in SRPT in Q2 2016 and has held it in 2 quarters since. 186 funds tracked by Wall St. Rank hold SRPT as of Q3 2016.

  • Emerald Acquisition held 23,351 shares of Sarepta Therapeutics worth $1.43M as of Q3 2016.
  • Emerald Acquisition sold 2,653 Sarepta Therapeutics shares in Q3 2016, an estimated $80.2K.
  • Sarepta Therapeutics made up ﹤0.01% of Emerald Acquisition's portfolio in Q3 2016, its #1932 holding.
  • Emerald Acquisition first reported a position in Sarepta Therapeutics in Q2 2016 and has held it in 2 quarters since.
  • 186 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.